@article{1ed13b247b014d3b82463e0c6a2915dd,
title = "EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy",
abstract = "Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).",
author = "Yang, {Hung Wei} and Lu, {Yu Jen} and Lin, {Kun Ju} and Hsu, {Sheng Chieh} and Huang, {Chiung Yin} and She, {Shu Han} and Liu, {Hao Li} and Lin, {Chih Wen} and Xiao, {Min Cong} and Wey, {Shiaw Pyng} and Chen, {Pin Yuan} and Yen, {Tzu Chen} and Wei, {Kuo Chen} and Ma, {Chen Chi M.}",
note = "Funding Information: We thank the National Science Council of the Republic of China , National Health Research Institutes of Taiwan , and Chang Gung Memorial Hospital , and National Tsing Hua University for financial support ( NSC 101-2120-M-182A-002-CCI , NHRI-EX102-10004NI , CMRPG3A0503 , CMRPG3C0351 , CMRPD1A0233 , CMRPG3A0041, 102N2024E1 , and 102N2772E1 ). The authors thank Dr. Yin-Cheng Huang for his technical assistance, Chang Gung Memorial Hospital Microscopy Core Laboratory and Animal Molecular Imaging Center for assistance with TEM, confocal microscopy and SPECT/CT tomography.",
year = "2013",
month = sep,
doi = "10.1016/j.biomaterials.2013.06.007",
language = "English",
volume = "34",
pages = "7204--7214",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "29",
}
